STOCK TITAN

Neurocrine Biosciences, Inc. - NBIX STOCK NEWS

Welcome to our dedicated news page for Neurocrine Biosciences (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neurocrine Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neurocrine Biosciences's position in the market.

Rhea-AI Summary
Neurocrine Biosciences, Inc. (NBIX) has initiated a Phase 1 clinical study for NBI-1065890, an investigational compound targeting neurological and neuropsychiatric conditions. The company aims to leverage its expertise in VMAT2 inhibition, following the success of valbenazine for tardive dyskinesia and Huntington's disease chorea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
clinical trial
-
Rhea-AI Summary
Neurocrine Biosciences, Inc. (NBIX) will participate in the UBS and Stifel virtual investor conferences in March 2024. Key executives will present at these events, discussing the company's latest developments and strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
conferences
-
Rhea-AI Summary
Neurocrine Biosciences, Inc. (NBIX) will participate in three investor conferences in March 2024, including the TD Cowen 44th Annual Healthcare Conference, Leerink Partners Global Biopharma Conference, and Barclays 26th Annual Global Healthcare Conference. Key executives will present at each event, with live webcasts available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
conferences
Rhea-AI Summary
Neurocrine Biosciences, Inc. reported net product sales of $500 million and $1.84 billion for the fourth quarter and full year of 2023, respectively, representing a year-over-year growth of 25% and 29%. The company provided full-year 2024 net product sales guidance of $2.1 - $2.2 billion. The FDA regulatory submission for crinecerfont for the treatment of Congenital Adrenal Hyperplasia is anticipated in the second quarter. The company's financial highlights include increased net product sales, GAAP and non-GAAP net income, and earnings per share. Recent developments include the resolution of patent litigation and the Breakthrough Therapy designation for crinecerfont. The company also provided its financial guidance for 2024 and expected pipeline milestones and key activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
earnings
-
Rhea-AI Summary
Neurocrine Biosciences, Inc. (NBIX) has scheduled its Q4 & Year-End 2023 financial results conference call and webcast for February 7, 2024. The press release and conference call will be held at 4:00 a.m. PT / 7:00 a.m. ET and 5:00 a.m. PT / 8:00 a.m. ET, respectively. The company has provided domestic and international dial-in numbers, along with the conference ID. The webcast will be available on the company's website and a replay will be archived for approximately one month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
earnings
-
Rhea-AI Summary
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
conferences
Rhea-AI Summary
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) received Breakthrough Therapy designation from the U.S. FDA for crinecerfont in congenital adrenal hyperplasia. The company is advancing the largest portfolio of muscarinic compounds in clinical development with top-line phase 2 data readouts for five programs anticipated in 2024, including NBI-'568, an M4 agonist, for the treatment of schizophrenia. Neurocrine is focused on building breadth and depth across therapeutic areas and modalities, including VMAT2 inhibition, CRF antagonism, muscarinic agonism to antagonism, and gene therapy. The company remains on track to advance two gene therapies into the clinic in 2025 and anticipates at least 20 development candidates by 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
Rhea-AI Summary
Neurocrine Biosciences, Inc. (NBIX) will hold an Analyst Day on December 5, 2023, focusing on R&D portfolio and strategy, featuring CEO Kevin Gorman and CSO Jude Onyia. The event will be held in-person and via webcast, with a live video webcast accessible on the company's website. A replay will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
conferences
-
Rhea-AI Summary
Neurocrine Biosciences, Inc. (NBIX) Resolves Patent Litigation for INGREZZA, Allowing Generic Versions to Enter US Market in 2038
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
none
Rhea-AI Summary
Neurocrine Biosciences, Inc. (NBIX) announced disappointing Phase 2 study results for NBI-921352 in focal onset seizures and NBI-1065846 in anhedonia. Both investigational drugs failed to meet their primary endpoints, impacting the company's pipeline programs in epilepsy and major depressive disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
Neurocrine Biosciences, Inc.

Nasdaq:NBIX

NBIX Rankings

NBIX Stock Data

13.72B
98.20M
1%
95.9%
2.5%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About NBIX

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders